The group had launched Avifavir in the market again in June 2020 with the assistance of Russian Direct Investment Fund (RDIF), turning into the primary pharmaceutical group to launch a direct antiviral for COVID-19 therapy. The product’s efficacy was confirmed with a full-scale scientific trial in Russia involving 460 COVID sufferers. The antiviral drug is presently being equipped to greater than 15 nations world wide as a part of the COVID therapy.
A meta-analysis of 23 COVID-19 therapy research for favipiravir demonstrated a 47 p.c enchancment when Favipiravir is used in early therapy of coronavirus. The scientific trials of Avifavir have demonstrated the presence of anti-COVID properties, akin to assuaging signs and chopping the period of the illness by half in comparison with the usual remedy.
The scientific trials performed for the medicinal drug Avifavir additionally proved that the virus is incapable of growing resistance to favipiravir even with long-term publicity on contaminated cells. This property of the drug gives it a bonus over extremely particular biologics and nucleoside merchandise that are susceptible to inducing fast evolution of resistant scientific variants.
Speaking about Avifavir, Elena Yakubova, Medical Director of ChemRar Group mentioned, “Having amassed in depth expertise with Avifavir in sufferers contaminated with COVID each from scientific trials and real-world scientific follow, we see that taking Avifavir in the primary three to 5 days after an infection results in a milder illness in most instances and prevents hospitalization. Over the previous 17 months, greater than 4 million sufferers have been handled with favipiravir worldwide. The product was nicely tolerated with no new adversarial occasions, which confirms the excessive security of favipiravir.”
Annotating that Avifavir can significantly reduce the progression of COVID disease, Robert Redfield, American Virologist and Former Director, U.S. Center for Disease Control and Prevention said, “Avifavir has been shown to be effective against COVID-19 in clinical trials and medical practice. Recently additional direct acting antiviral have been developed. Studying the combination of Avifavir with other antivirials such as Paklovid (Pfizer) could offer even better therapeutic options for those at higher risk of COVID-19 disease progression, reduce the likelihood of drug-resistant virus mutations, and increase the time after diagnosis when therapy can be effective”.
The results of Avifavir in real-world clinical practice is being closely monitored, with a retrospective review of its efficacy and safety currently under way in 40,000 patients exposed to the product in an outpatient or inpatient setting. It has till now demonstrated that if therapy begins in the first days after the onset of disease, the product significantly increases survival rate, reduces viral load, need for artificial ventilation, and length of hospital stay.
The potential of favipiravir against coronavirus infection was actively investigated in more than 50 clinical trials involving around 5,000 patients in Russia, Japan, China, India, Thailand, Turkey, Iran, Saudi Arabia, EU countries and Latin America. Over 700 publications in the database of international medical and biological literature have confirmed high efficacy and safety of favipiravir against COVID-19.